Emily Bodnar
Stock Analyst at HC Wainwright & Co.
(1.19)
# 1,488
Out of 4,641 analysts
206
Total ratings
27.27%
Success rate
-16.11%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Emily Bodnar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JSPR Jasper Therapeutics | Reiterates: Buy | $65 | $19.73 | +229.45% | 7 | Oct 24, 2024 | |
| RNAZ TransCode Therapeutics | Reiterates: Buy | $3 | $0.65 | +364.18% | 11 | Oct 24, 2024 | |
| OLMA Olema Pharmaceuticals | Reiterates: Buy | $30 | $11.61 | +158.51% | 13 | Oct 24, 2024 | |
| RCUS Arcus Biosciences | Initiates: Neutral | $20 | $17.60 | +13.67% | 1 | Oct 21, 2024 | |
| NVCR NovoCure | Upgrades: Buy | $24 → $30 | $16.35 | +83.44% | 13 | Oct 16, 2024 | |
| VTYX Ventyx Biosciences | Reiterates: Neutral | $6 | $2.19 | +173.97% | 13 | Oct 15, 2024 | |
| INKT MiNK Therapeutics | Reiterates: Buy | $9 | $0.72 | +1,144.30% | 9 | Oct 9, 2024 | |
| BCTX BriaCell Therapeutics | Reiterates: Buy | $15 | $0.87 | +1,622.16% | 10 | Oct 3, 2024 | |
| CNTX Context Therapeutics | Reiterates: Buy | $6 | $2.35 | +155.86% | 10 | Sep 23, 2024 | |
| PPBT Purple Biotech | Maintains: Buy | $8 → $33 | $4.56 | +623.68% | 13 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $1.23 | +879.59% | 9 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $22 | $7.98 | +175.69% | 9 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $1.21 | +891.16% | 11 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $1.22 | +558.44% | 4 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $18 → $6 | $5.97 | +0.50% | 10 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $2.55 | +1,154.90% | 4 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $14 | $0.92 | +1,417.29% | 8 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $22 | $3.70 | +494.59% | 13 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $55 | $33.60 | +63.71% | 3 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $6 | $1.42 | +322.30% | 6 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $11 | $3.78 | +191.01% | 5 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $40 → $9 | $4.40 | +104.78% | 9 | Jul 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $1.36 | +488.24% | 5 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $82 → $80 | $85.90 | -6.87% | 9 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $3.37 | - | 1 | Apr 25, 2024 |
Jasper Therapeutics
Oct 24, 2024
Reiterates: Buy
Price Target: $65
Current: $19.73
Upside: +229.45%
TransCode Therapeutics
Oct 24, 2024
Reiterates: Buy
Price Target: $3
Current: $0.65
Upside: +364.18%
Olema Pharmaceuticals
Oct 24, 2024
Reiterates: Buy
Price Target: $30
Current: $11.61
Upside: +158.51%
Arcus Biosciences
Oct 21, 2024
Initiates: Neutral
Price Target: $20
Current: $17.60
Upside: +13.67%
NovoCure
Oct 16, 2024
Upgrades: Buy
Price Target: $24 → $30
Current: $16.35
Upside: +83.44%
Ventyx Biosciences
Oct 15, 2024
Reiterates: Neutral
Price Target: $6
Current: $2.19
Upside: +173.97%
MiNK Therapeutics
Oct 9, 2024
Reiterates: Buy
Price Target: $9
Current: $0.72
Upside: +1,144.30%
BriaCell Therapeutics
Oct 3, 2024
Reiterates: Buy
Price Target: $15
Current: $0.87
Upside: +1,622.16%
Context Therapeutics
Sep 23, 2024
Reiterates: Buy
Price Target: $6
Current: $2.35
Upside: +155.86%
Purple Biotech
Sep 20, 2024
Maintains: Buy
Price Target: $8 → $33
Current: $4.56
Upside: +623.68%
Sep 16, 2024
Reiterates: Buy
Price Target: $12
Current: $1.23
Upside: +879.59%
Sep 16, 2024
Reiterates: Buy
Price Target: $22
Current: $7.98
Upside: +175.69%
Sep 12, 2024
Reiterates: Buy
Price Target: $12
Current: $1.21
Upside: +891.16%
Sep 6, 2024
Reiterates: Buy
Price Target: $8
Current: $1.22
Upside: +558.44%
Aug 15, 2024
Downgrades: Neutral
Price Target: $18 → $6
Current: $5.97
Upside: +0.50%
Aug 15, 2024
Reiterates: Buy
Price Target: $32
Current: $2.55
Upside: +1,154.90%
Aug 15, 2024
Reiterates: Buy
Price Target: $14
Current: $0.92
Upside: +1,417.29%
Aug 15, 2024
Maintains: Buy
Price Target: $23 → $22
Current: $3.70
Upside: +494.59%
Aug 14, 2024
Reiterates: Buy
Price Target: $55
Current: $33.60
Upside: +63.71%
Aug 12, 2024
Reiterates: Buy
Price Target: $6
Current: $1.42
Upside: +322.30%
Aug 9, 2024
Maintains: Buy
Price Target: $12 → $11
Current: $3.78
Upside: +191.01%
Jul 18, 2024
Downgrades: Neutral
Price Target: $40 → $9
Current: $4.40
Upside: +104.78%
Jun 3, 2024
Reiterates: Buy
Price Target: $8
Current: $1.36
Upside: +488.24%
May 13, 2024
Maintains: Buy
Price Target: $82 → $80
Current: $85.90
Upside: -6.87%
Apr 25, 2024
Reiterates: Neutral
Price Target: n/a
Current: $3.37
Upside: -